Skip to main content
MedinCell S.A. logo

MedinCell S.A. — Investor Relations & Filings

Ticker · MEDCL ISIN · FR0004065605 LEI · 969500R79U6PXCL2FF46 PA Manufacturing
Open in API
Filings indexed 522 across all filing types
Latest filing 2023-09-06 Board/Management Inform…
Country FR France
Listing PA MEDCL

About MedinCell S.A.

https://www.medincell.com/en/

MedinCell S.A. is a pharmaceutical company at the commercial stage that specializes in the development of long-acting injectable (LAI) therapies. The company's core is its proprietary BEPO® technology platform, which enables the controlled and sustained release of active pharmaceutical ingredients over periods ranging from days to months after a single injection. This technology forms a fully biodegradable depot in situ, designed to improve treatment efficiency, enhance patient compliance, and increase the global accessibility of medicines. MedinCell develops a portfolio of LAI products across various therapeutic areas, including psychiatry, advancing its pipeline through both internal research and strategic partnerships with other pharmaceutical organizations.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Board/Management Information Classification · 99% confidence The document is a press release dated September 6, 2023, announcing the hiring of Dr. Grace Kim to lead US Biopharma Financial & IR Strategy. This announcement concerns a change in senior management/personnel, specifically the addition of a key executive responsible for Investor Relations and financial strategy. This aligns directly with the definition of 'Board/Management Information' (MANG), which covers announcements of changes in senior management.
2023-09-06 English
Informations privilégiées / Autres communiqués
Board/Management Information Classification · 99% confidence The document is a press release dated September 6, 2023, announcing the hiring of Dr. Grace Kim to a strategic role focused on financial strategy and investor relations in the US biopharma sector. The text details her background, responsibilities, and quotes from management. This type of announcement, concerning changes in senior personnel (Board or Management), directly aligns with the definition for Board/Management Information (MANG). It is not a financial report (10-K, IR, ER), a shareholder vote result (DVA), or a general regulatory filing (RNS), but a specific personnel announcement.
2023-09-06 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated August 30, 2023, announcing the successful completion of patient recruitment for a Phase 3 clinical study (F14/mdc-CWM) for a drug treatment. It details clinical progress, expected results timeline (Q1 2024), and provides context about the drug and the company (MedinCell). This type of announcement, focusing on key operational and clinical milestones rather than full financial statements (like 10-K or IR) or a formal transcript (CT), is characteristic of an Earnings Release (ER) or a general operational update. Since it focuses on clinical trial progress and operational milestones rather than just quarterly financial highlights, it fits best as a general operational announcement. However, given the options, announcements of significant operational progress, especially those related to product development and clinical trials, often accompany or substitute for an Earnings Release (ER) if financial data is minimal or secondary. Since it is a formal announcement of a significant business event (completion of recruitment for Phase 3), and it is not a transcript, a formal report, or a proxy statement, it aligns most closely with the function of an Earnings Release (ER) which communicates key period updates, or potentially a Regulatory Filing (RNS) if it were less structured. Given the structure (headline, bullet points of key achievements, quotes, boilerplate 'About Us'), it strongly resembles a standard press release used for major operational news, which often falls under the 'Earnings Release' category when reporting on operational progress, even if specific quarterly financials aren't the main focus. It is not a Report Publication Announcement (RPA) because it contains substantive news, not just a notice that a report is available. Therefore, ER is the most appropriate fit for a major operational/clinical update press release.
2023-08-30 French
Inside Information / Other news releases
Regulatory Filings Classification · 98% confidence The document is titled "MedinCell announces successful completion of patient enrollment in the Phase 3 study of F14..." and is dated August 30, 2023. It details clinical trial progress (enrollment completion, next steps, anticipated results in Q1 2024) and provides company background and contact information. This structure is characteristic of a press release announcing a significant operational or clinical milestone, rather than a formal regulatory filing like a 10-K, an Interim Report (IR), or a specific financial disclosure. Since it is an announcement of operational news, it fits best under the general category for regulatory announcements that are not otherwise specified, which is Regulatory Filings (RNS), or potentially an Earnings Release (ER) if it were tied to a reporting period, but here it is purely clinical/operational news. Given the options, RNS serves as the best general category for corporate press releases that don't fit the highly specific financial/governance codes.
2023-08-30 English
Terms of availability of the preparatory documents for the GM
AGM Information Classification · 98% confidence The document explicitly discusses the 'Annual General Meeting and Extraordinary General Meeting' (AGM/EGM), detailing the date, location, participation terms, remote voting procedures (Votaccess), and a presentation event regarding the resolutions. This content directly relates to the logistics, materials, and information shared concerning the Annual General Meeting. Therefore, the most appropriate classification is AGM Information (AGM-R).
2023-08-21 English
Modalités de mise à disposition des documents préparatoires à l'AG
AGM Information Classification · 98% confidence The document is titled "Modalités de participation à l'Assemblée Générale Mixte des actionnaires" (Participation modalities for the Combined General Meeting of Shareholders). It explicitly details the date, time, location, and voting procedures (Votaccess, mail, in person) for the upcoming Annual General Meeting (AGM) scheduled for September 12, 2023. It also mentions a preparatory videoconference on September 5, 2023, to present the resolutions. This content directly relates to the logistics and information surrounding the AGM. Therefore, the most appropriate classification is AGM Information (AGM-R).
2023-08-21 French

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.